- Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)
- Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues
- The safety profile of atacicept was favorable, and comparable to placebo
- Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027
- Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2
For more information about the ORIGIN 3 clinical trial (NCT04716231), please visit http://www.clinicaltrials.gov.
The Company will host an investor call and webcast to discuss the data update at 8:00 AM ET on Monday, June 2.
Investors Dial-in: 1-877-425-9470
Int’l Investors Dial-in: 1-201-389-0878
Conference ID: 13754147
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1722931&tp_key=818ddad936
The live webcast will be available on the Company’s Investor Calendar, with the recording and presentation available immediately following the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.